S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NYSE:MDTMedtronic Stock Price, Forecast & News

$100.72
+0.34 (+0.34 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$100.52
Now: $100.72
$102.49
50-Day Range
$88.77
MA: $94.67
$100.72
52-Week Range
$72.13
Now: $100.72
$122.15
Volume4.46 million shs
Average Volume6.21 million shs
Market Capitalization$135.10 billion
P/E Ratio28.37
Dividend Yield2.30%
Beta0.67
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation product; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Minimally Invasive Therapies Group segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, hernia mechanical devices, mesh implants, and gynecology products; hardware instruments and mesh fixation device; and gastrointestinal, inhalation therapy, and renal care solutions. The Restorative Therapies Group segment offers products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, colorectal surgeons, urogynecologists, interventional radiologists, and ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems; and therapies for vasculature in and around the brain. The Diabetes Group segment offers insulin pumps and consumables, continuous glucose monitoring systems, and therapy management software. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Read More
Medtronic logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.3Dividend Strength: 4.2Insider Behavior: 1.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.87 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP58505510
Phone353-1438-1700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$28.91 billion
Cash Flow$6.66 per share
Book Value$37.96 per share

Profitability

Net Income$4.79 billion

Miscellaneous

Employees90,000
Outstanding Shares1,341,299,000
Market Cap$135.10 billion
Next Earnings Date8/25/2020 (Confirmed)
OptionableOptionable
$100.72
+0.34 (+0.34 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MDT News and Ratings via Email

Sign-up to receive the latest news and ratings for MDT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Medtronic (NYSE:MDT) Frequently Asked Questions

How has Medtronic's stock been impacted by Coronavirus?

Medtronic's stock was trading at $92.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MDT stock has increased by 9.0% and is now trading at $100.72.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Medtronic?

30 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medtronic in the last year. There are currently 1 sell rating, 6 hold ratings, 22 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Medtronic
.

When is Medtronic's next earnings date?

Medtronic is scheduled to release its next quarterly earnings announcement on Tuesday, August 25th 2020.
View our earnings forecast for Medtronic
.

How can I listen to Medtronic's earnings call?

Medtronic will be holding an earnings conference call on Tuesday, August 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Medtronic's earnings last quarter?

Medtronic PLC (NYSE:MDT) released its earnings results on Thursday, May, 21st. The medical technology company reported $0.58 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.28 by $0.70. The medical technology company had revenue of $6 billion for the quarter, compared to analysts' expectations of $6.10 billion. Medtronic had a net margin of 16.56% and a return on equity of 12.17%. The firm's revenue for the quarter was down 26.4% on a year-over-year basis. During the same period last year, the company earned $1.54 EPS.
View Medtronic's earnings history
.

How often does Medtronic pay dividends? What is the dividend yield for Medtronic?

Medtronic declared a quarterly dividend on Thursday, May 21st. Stockholders of record on Friday, June 26th will be paid a dividend of $0.58 per share on Friday, July 17th. This represents a $2.32 dividend on an annualized basis and a dividend yield of 2.30%. The ex-dividend date is Thursday, June 25th. This is a boost from Medtronic's previous quarterly dividend of $0.54.
View Medtronic's dividend history
.

What price target have analysts set for MDT?

30 analysts have issued twelve-month price objectives for Medtronic's shares. Their forecasts range from $92.00 to $135.00. On average, they anticipate Medtronic's stock price to reach $114.53 in the next twelve months. This suggests a possible upside of 13.7% from the stock's current price.
View analysts' price targets for Medtronic
.

What are Wall Street analysts saying about Medtronic stock?

Here are some recent quotes from research analysts about Medtronic stock:
  • 1. According to Zacks Investment Research, "Medtronic’s lower-than-expected earnings and weak performances demonstrated by the company at CER, backed by dismal performance in all major business segments and geographies are concerning. The company’s performance was primarily impacted from deferred procedures due to the pandemic. Escalating costs and expenses persistently put pressure on its margins. Unfavorable currency movement once again deterred growth in the quarter. Over the past six months, Medtronic underperformed its industry. Yet, it saw significant growth in airways and ventilators sales in the fourth quarter of fiscal 2020 amid the pandemic. It is currently focusing on the geographical diversification of its businesses, apart from product innovation. Also, Medtronic demonstrated a strong solvency position. Its fourth quarter performance saw better-than-expected revenues." (7/29/2020)
  • 2. Northland Securities analysts commented, "We continue to wait for a definitive breakout in key categories in terms of growth. In fairness, Medtronic continues to improve operational efficiencies." (8/21/2019)

Has Medtronic been receiving favorable news coverage?

Headlines about MDT stock have trended very negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Medtronic earned a media sentiment score of -3.9 on InfoTrie's scale. They also gave media headlines about the medical technology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days.
View the latest news about Medtronic
.

Are investors shorting Medtronic?

Medtronic saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 9,560,000 shares, a decline of 23.2% from the March 31st total of 12,450,000 shares. Based on an average daily volume of 7,460,000 shares, the short-interest ratio is presently 1.3 days.
View Medtronic's Short Interest
.

Who are some of Medtronic's key competitors?

What other stocks do shareholders of Medtronic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medtronic investors own include Johnson & Johnson (JNJ), AT&T (T), Walt Disney (DIS), AbbVie (ABBV), NVIDIA (NVDA), Cisco Systems (CSCO), Intel (INTC), CVS Health (CVS), Home Depot (HD) and JPMorgan Chase & Co. (JPM).

Who are Medtronic's key executives?

Medtronic's management team includes the following people:
  • Mr. Omar S. Ishrak, Chairman & CEO (Age 63)
  • Ms. Karen L. Parkhill, Exec. VP, CFO & Principal Accounting Officer (Age 54)
  • Mr. Bradley E. Lerman, Sr. VP, Gen. Counsel & Company Sec. (Age 61)
  • Mr. Michael J. Coyle, Exec. VP and Group Pres of Cardiac & Vascular Group (Age 57)
  • Mr. Robert J. W. ten Hoedt, Exec. VP and Group Pres, Europe, Middle East & Africa (Age 58)

What is Medtronic's stock symbol?

Medtronic trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."

Who are Medtronic's major shareholders?

Medtronic's stock is owned by many different retail and institutional investors. Top institutional investors include Bank of New York Mellon Corp (1.33%), Sanders Capital LLC (0.56%), Swiss National Bank (0.44%), California Public Employees Retirement System (0.38%), Principal Financial Group Inc. (0.34%) and Pendal Group Ltd (0.29%). Company insiders that own Medtronic stock include Bradley E Lerman, Carol A Surface, Geoffrey Martha, Hoedt Rob Ten, Hooman Hakami, Karen L Parkhill, Michael J Coyle, Omar Ishrak, Richard H Anderson, Richard Kuntz and Robert John White.
View institutional ownership trends for Medtronic
.

Which institutional investors are selling Medtronic stock?

MDT stock was sold by a variety of institutional investors in the last quarter, including AJO LP, Prudential Financial Inc., Cooke & Bieler LP, Prudential PLC, Hexavest Inc., Comgest Global Investors S.A.S., Factory Mutual Insurance Co., and Victory Capital Management Inc.. Company insiders that have sold Medtronic company stock in the last year include Carol A Surface, Hooman Hakami, Michael J Coyle, Richard Kuntz, and Robert John White.
View insider buying and selling activity for Medtronic
.

Which institutional investors are buying Medtronic stock?

MDT stock was purchased by a variety of institutional investors in the last quarter, including Sarasin & Partners LLP, Fisher Asset Management LLC, Sanders Capital LLC, DAVENPORT & Co LLC, Bank of New York Mellon Corp, Bank of Nova Scotia, Sector Gamma AS, and Principal Financial Group Inc.. Company insiders that have bought Medtronic stock in the last two years include Karen L Parkhill, Omar Ishrak, and Richard H Anderson.
View insider buying and selling activity for Medtronic
.

How do I buy shares of Medtronic?

Shares of MDT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Medtronic's stock price today?

One share of MDT stock can currently be purchased for approximately $100.72.

How big of a company is Medtronic?

Medtronic has a market capitalization of $135.10 billion and generates $28.91 billion in revenue each year. The medical technology company earns $4.79 billion in net income (profit) each year or $4.59 on an earnings per share basis. Medtronic employs 90,000 workers across the globe.

What is Medtronic's official website?

The official website for Medtronic is www.medtronic.com.

How can I contact Medtronic?

Medtronic's mailing address is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. The medical technology company can be reached via phone at 353-1438-1700 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.